Loading clinical trials...
Loading clinical trials...
A Phase IB (Repeat Dosing) Trial of Second Dose Oncolytic HSV Administered Intratumorally in Patients With Recurrent Malignant Glioma.
Conditions
Interventions
C134 Re-Administration
Locations
1
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Start Date
June 21, 2024
Primary Completion Date
March 7, 2025
Completion Date
March 7, 2025
Last Updated
January 22, 2026
NCT05278208
NCT06146725
NCT03213652
NCT04195555
NCT07448480
NCT02658279
Lead Sponsor
University of Alabama at Birmingham
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions